Artelo Biosciences, Inc. (ARTL) stock rose 15.77 percent to $5.14, gaining $0.70 on Monday, following the publication of new research supporting its non-opioid pain therapy approach.
The stock is currently trading at $5.14, compared to its previous close of $4.44 on the Nasdaq. During the session, it reached a high of $5.64 and a low of $4.79, with trading volume climbing to 29,255,913 shares, well above its average volume of 2,882,845.
The move comes after the company announced a peer-reviewed article highlighting FABP5 as a promising therapeutic target for pain management. Preclinical data showed consistent analgesic effects across multiple pain models, supporting the potential of its candidate ART26.12 as a novel, non-opioid treatment. Artelo Biosciences' 52-week range is $2.95 to $85.80.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.